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lation between hematologic and organ response.
Results:Median age at auto-HCTwas 59 years (range, 41-74).
Median time from diagnosis to auto-HCT was 6.6 months
(2.2-121.9). Additional visceral organs involved were: heart 5
pts (9%), GI tract 3 pts (5%), peripheral nerves 1 pt (2%) and
liver 5 pts (9%). Median baseline 24-hour proteinuria was
5.055 grams (range, 0.17- 27.85 grams). All pts received
melphalan or melphalan-based combinations as their
preparative regimen.Median time to neutrophil engraftment
was 10 days (range, 7-15). Median follow up from auto-HCT
was 24.5 months (range, 0.4-132). Six pts died of non-relapse
causes with a non-relapse mortality (NRM) at both 100 days
and 1 year of 10.9%. Fifty pts were evaluable for a hemato-
logic response, while 5 patients were inevaluable due to
early death. Eight pts (16%) achieved complete remission
(CR), 10 (20%) achieved a very good partial remission (VGPR)
and 21 (42%) achieved a partial remission (PR), with an
overall response rate of 78%. Organ response was evaluated
at 6, 12, and 24 months, and was deﬁned as a 50% decrease
in total proteinuria over 24 hours without an increase of
25% of serum creatinine. Organ response was demon-
strated in 8 (17%) of 47 evaluable pts at 6 months, in 11 (29%)
of 38 evaluable pts at 12 months, and in 12 (44%) of 27
evaluable pts at 24 months, respectively. Organ responses at
last follow up were seen in 12 of 28 pts with > hematologic
PR and 0 of 11 pts with < hematologic PR (P ¼ .008). Two pts
who were hemodialysis-dependent pre auto-HCT remained
on dialysis after the auto-HCT. Median PFS and OS were 43.1
and 69.9 months, respectively. Kaplan-Meier estimates of 3-
year PFS and OS were 62% and 73%, respectively (Figure 1). At
the time of last follow-up, 37 pts (67%) were alive and in
remission.
Conclusions: High-dose melphalan and auto-HCT is associ-
ated with durable hematologic and organ response, and long
OS in patients with AL and renal involvement. Achievement
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Minneapolis, MNCD20 is a trans-membrane protein expressed onmature B
cells through all stages of their development. However, its
expression is down regulated at the point of differentiation
into plasma cells and expressed only in 16-22% of mature
plasma cells. CD20 expression on plasma cells has been
described with both favorable prognosis in association with
translocation t(11;14) and unfavorable prognosis in associa-
tion with plasma cell leukemia. The incidence of CD20
expression on plasma cells from patients with relapsed/
refractory multiple myeloma is not well stated in literature
and not routinely done in this patients' population. Addi-
tionally, it is not known if CD20 represents a primary aberrant
expression in newly diagnosed cases of multiple myeloma or
possibly represents a secondary genetic change at the time of
relapse related to hypothesized myeloma stem cells.
In order to study the above questions, we retrospectively
reviewed the medical records of 92 patients with symp-
tomatic MM who underwent ASCT between January 2008
and December 2011. As of July 2012, 38 patients have
relapsed. Bone marrow biopsy and ﬂow cytometry results
were available for 33 patients at time of diagnosis and
relapse. CD20 expression was positive on plasma cells by
ﬂow cytometry in 11 out of 33 patients (33%) at time of
relapse. Interestingly, CD20 expression at diagnosis was
negative in 4 out of these 11 patients. This up-regulation in
CD 20 expressionwas associatedwith clonal evolution in two
patients (deletion-17 and complex hypo-diploid cytogenetic,
respectively). Conﬁrmatory immune-histochemical staining
for CD20 was positive only in 2 of these 4 patients.
Conclusion: CD20 expression on plasma cells at time of
relapse/progression can occur in one third of patients with
multiple myeloma and may provide an additional thera-
peutic target. The cause of discrepancy between CD20
expression by ﬂow cytometry and immune-histochemical
staining is unclear and suggests that the two methods may
be complementary for a comprehensive evaluation of CD20
expression in multiple myeloma. CD20 up-regulation in
patients with relapsed/refractory myeloma who were
previously CD20 negative at diagnosis may represent
a secondary genetic event heralding a more aggressive
disease. Future prospective studies evaluating CD20 expres-
sion on plasma cells at different stages of disease progression
may optimize the timing for anti-CD20 therapy while har-
nessing the concept of colonogeneic myeloma stem cells.246
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Background: AL is characterized by the production of
monoclonal light chains which misfold, deposit in various
organs, including the heart, and cause early death. High dose
melphalan with SCT results in high hematologic response
(HR) rates and is standard treatment for eligible patients.
Achieving a CR to SCT results in extended EFS and OS. We
have studied novel agents as consolidation following
